Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • CDSCO issues advisory...

    CDSCO issues advisory on Labelling requirements for MTP combo kit of Misoprostol, Mifepristone tablet, Details

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-25T13:30:52+05:30  |  Updated On 25 Aug 2019 1:30 PM IST
    CDSCO issues advisory on Labelling requirements for MTP combo kit of Misoprostol, Mifepristone tablet, Details

    New Delhi: The apex drug regulatory body, Central Drugs Standard Control Organisation(CDSCO) has recently issued an advisory on labelling requirements for combi kit of Misoprostol and Mifepristone tablets for Medical Termination of Pregnancy (MTP).


    The drugs mifepristone and misoprostol fall under the National List of Essential Medicines. The combo kit of Misoprostol and Mifepristone tablets for abortion is manufactured by various drugmakers including Cipla under the brand name MTprost (200mg/ 200mcg), Zydus Cadila sells it as Mifegest Kit and so on.


    The availability of MTP kit has become quite accessible as online pharmacies supply the goods like MTP kits reportedly without confirming the authenticity of the prescription and patient. This paves way for tighter labelling norms to avoid adverse results.


    The advisory comes following the deliberation of the issue of labelling requirements for combi kit of Misoprostol and Mifepristone on te matter. The concern was taken up in the 56th Drugs Consultative Committee (DCC) meeting held a couple of months ago.



    In the meeting, the DCC suggested that a letter should be issued by CDSCO to all State Drugs Controllers about the labelling requirements and also to ensure the effective implementation of labelling requirements as per MTP provisions.

    The combi kit of Misoprostol and Mifepristone tablets (1 uncoated mifepristone 200 mg tablet + 4 uncoated misoprostol 200 meg tablets) for MTP was approved in 2018 by CDSCO with the following warning:




    “Warning: product is to be used only under the supervision of a service provider and in a medical facility as specified under MTP Act 2002 & MTP Rules 2003”



    Also Read: Mumbai: FDA raid at Medical Store reveals hundreds of illegal MTP kits


    With the advisory, all the State and Union Territory drug controllers are now directed via the CDSCO notice to ensure the effective implementation of labelling requirements for Combi kit of Misoprostol and Mifepristone tablets as per the provisions of Drugs and Cosmetics Act, 1940 & Rules, 1945 and MTP Act, 2002 & MTP Rules, 2003 which intends to safeguard the health of a woman seeking an abortion and prevent sex-selective abortions.


    Also Read: Bahart Bandh: Nationwide strike by 8.5 lakh chemists and Retailers

    (DCC)abortion pillsCDSCOCentral Drugs Standard Control OrganisationCiplaCombi kitDrugs Consultative CommitteeDTABMedical Termination of PregnancyMifegest KitMifepristoneMisoprostolmtpMTP Act 2002MTP Rules 2003mtprostNational List of Essential MedicinesNLEMpregnancy terminationZydus Cadila

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok